Thailand Cancer Immunotherapy Market Report 2022 to 2030

Thailand Cancer Immunotherapy Market Analysis

$ 3999

Thailand's cancer immunotherapy market is expected to witness growth from $135 Mn in 2022 to $240 Mn in 2030 with a CAGR of 7.4% for the forecasted year 2022-30. The increasing incidence of cancer and the improvements in healthcare spending in Thailand are responsible for the growth of the market. The Thailand cancer immunotherapy market is segmented by type, application, and end user. Silom Medical, Emergpharma, and Bayer are the major players in the Thailand cancer immunotherapy market.

ID: IN10THPH032 CATEGORY: Pharmaceuticals GEOGRAPHY: Thailand AUTHOR: Dr. Parul Choudhary

Buy Now

Thailand Cancer Immunotherapy Market Executive Analysis

Thailand's cancer immunotherapy market is expected to witness growth from $135 Mn in 2022 to $240 Mn in 2030 with a CAGR of 7.4% for the forecasted year 2022-30. The Universal Coverage Scheme would receive $6 Bn in the fiscal year 2023, an increase of 4.12% from the prior year, as agreed by the Thai cabinet. The recently introduced services are mostly associated with COVID-19, including costs for RT-PCR tests, antigen test kits (ATKs), and services for COVID-19 immunization.

With an age-adjusted mortality rate of 89.7 per 100 000 for males and 67.2 per 100 000 for females in Khon Kaen 133.3 for males and 121.0 for females in Chiang Mai, cancer has been the top cause of death in Thailand. Immunotherapy is a kind of cancer treatment that strengthens the body's inbuilt defences against cancer. It aids in the immune system's ability to identify cancer cells and fortify its reactions, enabling the immune system to kill the cancer cells. Checkpoint inhibitors are a type of immunotherapy used to treat cancer, including nivolumab and pembrolizumab. They suppress the signal that would have stopped white blood cells with activated T-cell receptors from attacking cancer cells. The US and Thai FDAs have both approved both medications. Compared to chemotherapy, both medications have been demonstrated to slow the advancement of the disease and improve the survival rate of cancer patients. Additionally, compared to chemotherapy, radiation therapy has fewer adverse effects like bone marrow suppression, nausea, and vomiting. As a result, they are frequently employed as cancer treatments in several nations.

Thailand Cancer Immunotherapy Market Analysis

Market Dynamics

Market Growth Drivers

With a high incidence rate and an increasing number of cases each year, cancer is a significant public health concern in Thailand. As a result, effective cancer therapies like immunotherapy are in more demand. The Thai government has been aggressively pushing for the growth of the biopharmaceutical sector and has unveiled a number of programs to aid in the expansion of the Thailand cancer immunotherapy market. Thailand has been spending more on healthcare recently, and this trend is anticipated to continue. Increased funding for cancer therapies, particularly immunotherapy, is likely to arise from this. The creation of more effective and targeted immunotherapies is now possible because of technological developments like next-generation sequencing and personalized medicine, which are predicted to accelerate Thailand's cancer immunotherapy market growth.

Market Restraints

Cancer immunotherapy can be expensive, and this expense could be a major obstacle to its acceptance in Thailand, especially given the country's healthcare system, which relies heavily on patients paying out of pocket. This may reduce the market's ability to expand. Many patients may find it difficult to get immunotherapy because the Thai government's reimbursement procedures are still comparatively lax, especially for those who cannot afford to pay out of pocket. Although immunotherapy is becoming more well-known and accepted in Thailand, some patients and medical professionals might still be dubious about its efficacy, which could limit demand and adoption thereby limiting the expansion of the Thailand cancer immunotherapy market.

Competitive Landscape

Key Players

VE Healthcare Group (THA)
OLIC (THA)
Pacific Healthcare Group (THA)
Silom Medical (THA)
Emergpharma (THA)
Bayer
AstraZeneca
Bristol-Myers Squibb
F. Hoffmann-La Roche
Pfizer
Eli Lily
Novartis

Healthcare Policies and Regulatory Landscape

The National Health Security Office (NHSO) and the Universal Coverage Scheme (UCS) are in charge of overseeing the healthcare system's insurance plans and payment procedures for cancer therapies like immunotherapy in Thailand. The bulk of the populace is covered by the UCS, a public health insurance program, which includes cancer sufferers. It makes a variety of cancer treatments, such as chemotherapy, radiation therapy, and surgery, accessible. Immunotherapy coverage, however, may have restrictions, and some patients may be required to pay out of cash for these therapies. The NHSO is in charge of managing the government's healthcare budget and approving payments for cancer treatments. The Thai Food and Drug Administration (FDA) must approve a cancer treatment before it can be paid for. It must also meet specific requirements, such as being clinically effective, secure, and economical. The NHSO and the UCS often fund immunotherapy treatments, but coverage may change based on the precise immunotherapy regimen and the patient's unique situation. Patients could have to cover some of the expense of immunotherapy out-of-pocket, and some immunotherapy therapies would need prior NHSO approval before they can be reimbursed.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Immunotherapy Segmentation

By Type (Revenue, USD Billion):

Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
PD-1/PD-L1
CTLA-4

By Application (Revenue, USD Billion):

Lung Cancer
Breast Cancer
Head and Neck Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Others

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers (ASCs)
Cancer Research Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

Silom Medical, Emergpharma, and Bayer are the major players in the Thailand cancer immunotherapy market.

The Thailand cancer immunotherapy market is expected to grow from $135 Mn in 2022 to $240 Mn in 2030 with a CAGR of 7.4% for the forecasted year 2022-2030.

The Thailand cancer immunotherapy market is segmented by type, application, and end user.